	US 12,144,816 B2
	Substituted indole Mcl-1 inhibitors
Taekyu Lee, Brentwood, TN (US); James C. Tarr, Franklin, TN (US); KyuOk Jeon, Nashville, TN (US); James M. Salovich, Nashville, TN (US); Subrata Shaw, Nashville, TN (US); Nagarathanam Veerasamy, Nashville, TN (US); Kwangho Kim, Nashville, TN (US); Plamen P. Christov, Mount Juliet, TN (US); Edward T. Olejniczak, Nashville, TN (US); Bin Zhao, Brentwood, TN (US); Stephen W. Fesik, Nashville, TN (US); and Zhiguo Bian, Lake Bluff, IL (US)
Assigned to Vanderbilt University, Nashville, TN (US)
Filed by Vanderbilt University, Nashville, TN (US)
Filed on Dec. 9, 2022, as Appl. No. 18/064,206.
Application 18/064,206 is a continuation of application No. 16/081,709, granted, now 11,596,639, previously published as PCT/US2017/020699, filed on Mar. 3, 2017.
Claims priority of provisional application 62/402,903, filed on Sep. 30, 2016.
Claims priority of provisional application 62/304,124, filed on Mar. 4, 2016.
Prior Publication US 2023/0330099 A1, Oct. 19, 2023
Int. Cl. A61K 31/551 (2006.01); A61K 31/4985 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/538 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/14 (2006.01); C07D 487/04 (2006.01); C07D 519/00 (2006.01)

CPC A61K 31/551 (2013.01) [A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/538 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/14 (2013.01); C07D 487/04 (2013.01); C07D 519/00 (2013.01)]

16 Claims

1. A compound having formula:

or a pharmaceutically acceptable salt thereof, wherein:

R³is

L⁴-R^wis